John CFA - Inari Medical Vice Relations
NARIDelisted Stock | USD 79.97 0.00 0.00% |
Executive
John CFA is Vice Relations of Inari Medical
Phone | 877 923 4747 |
Web | https://www.inarimedical.com |
Inari Medical Management Efficiency
The company has return on total asset (ROA) of (0.0321) % which means that it has lost $0.0321 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1772) %, meaning that it created substantial loss on money invested by shareholders. Inari Medical's management efficiency ratios could be used to measure how well Inari Medical manages its routine affairs as well as how well it operates its assets and liabilities.Inari Medical currently holds 32.05 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Inari Medical has a current ratio of 9.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Inari Medical's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Showing other executives | EXECUTIVE Age | ||
James Hart | Progyny | N/A | |
Mark MS | Outset Medical | 67 | |
James JD | Legend Biotech Corp | N/A | |
Steven Williamson | Outset Medical | 51 | |
Jennifer Sipple | Outset Medical | N/A | |
Deborah Wong | Legend Biotech Corp | N/A | |
Mythili MD | Legend Biotech Corp | 46 | |
Tina Carter | Legend Biotech Corp | N/A | |
Katie Higgins | Progyny | N/A | |
Surabhi Verma | Legend Biotech Corp | N/A | |
Birk Vanderweeen | Legend Biotech Corp | N/A | |
Laura Romike | Outset Medical | N/A | |
Doug Wallace | Legend Biotech Corp | N/A | |
John JD | Outset Medical | 50 | |
Arielle Bogorad | Progyny | N/A | |
John Brottem | Outset Medical | 49 | |
Steven Leist | Progyny | N/A | |
Cassandra Pratt | Progyny | N/A | |
Mark CPA | Progyny | 58 | |
Shu Wu | Legend Biotech Corp | N/A | |
Dinamarie Stefani | Outset Medical | N/A |
Management Performance
Return On Equity | -0.18 | ||||
Return On Asset | -0.0321 |
Inari Medical Leadership Team
Elected by the shareholders, the Inari Medical's board of directors comprises two types of representatives: Inari Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inari. The board's role is to monitor Inari Medical's management team and ensure that shareholders' interests are well served. Inari Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inari Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Angela JD, General Secretary | ||
Tara Dunn, Senior Development | ||
John Borrell, Senior Sales | ||
Kevin Strange, Accounting, Finance | ||
Janet Byk, VP Accounting | ||
John CFA, Vice Relations | ||
Karen Silva, Vice Accounting | ||
Tim Benner, Chief Officer | ||
Eric Khairy, Senior Marketing | ||
Neil Bhalodkar, Vice Relations | ||
Angela Ahmad, General Secretary | ||
Dena Truelove, VP HR | ||
Paul Koehn, Senior Operations | ||
William Hoffman, Pres CEO | ||
Brian Strauss, Senior Engineering | ||
Hussain Rangwala, Chief Officer | ||
Andrew Hykes, Chief Officer | ||
Shannon Trevino, General Secretary | ||
Mitchell Hill, Chief Officer | ||
Thomas MD, Chief Officer | ||
MPH MD, Chief LimFlow |
Inari Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inari Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.18 | ||||
Return On Asset | -0.0321 | ||||
Profit Margin | (0.14) % | ||||
Operating Margin | (0.04) % | ||||
Current Valuation | 4.6 B | ||||
Shares Outstanding | 58.56 M | ||||
Shares Owned By Insiders | 8.99 % | ||||
Shares Owned By Institutions | 95.50 % | ||||
Number Of Shares Shorted | 2.48 M | ||||
Price To Earning | 275.35 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Inari Stock
If you are still planning to invest in Inari Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Inari Medical's history and understand the potential risks before investing.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |